Anti-Human A33 Recombinant Antibody (KRN330) (CAT#: TAB-002CL)

Figure 1 Immunohistochemistry staining of biopsy samples.

Positive staining was observed for both A33 expression and KRN330 binding from patients biopsied on Day 8, 9 or 14 following initial dosing of 3 mg/kg. Although
one of the specimens was obtained by fine needle aspiration, as opposed to core biopsy, positive staining for A33 expression was observed on the membrane of tumour cells. Control tissue from cynomolgus monkeys and commercially available human CRC tissue demonstrated positive binding for A33 and binding of KRN330 only in tissue from animals exposed to KRN330.

Infante, J. R., Bendell, J. C., Goff, L. W., Jones, S. F., Chan, E., Sudo, T., ... & Berlin, J. D. (2013). Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancer. European Journal of Cancer, 49(6), 1169-1175.